Paper33536615
IgA transcytosis and antigen recognition govern ovarian cancer immunity.
Biswas S and 22 others. Nature, 2021. Cited by 207 papers, by iCite.
Cite this record
ConductScience Library. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Papers, record 33536615. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33536615
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, Neoplasm | Major topic |
| Immunoglobulin A | Major topic |
| Ovarian Neoplasms | Major topic |
| T-Lymphocytes, Cytotoxic | Major topic |
| Transcytosis | Major topic |
| Antibody Specificity | |
| Antigens, CD | |
| Cell Line | |
| Disease Progression | |
| Female | |
| Humans | |
| Receptors, Fc | |
| Signaling Lymphocytic Activation Molecule Family | |
| Tumor Microenvironment |
Source PubMed
Grants17
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA233512 | NCI NIH HHS | United States | R01CA233512 | PubMed | NIH RePORTER |
| UM1 CA186107 | NCI NIH HHS | United States | UM1CA186107 | PubMed and NIH | NIH RePORTER |
| R01 CA157664 | NCI NIH HHS | United States | R01CA157664 | PubMed and NIH | NIH RePORTER |
| R01 CA262121 | NCI NIH HHS | United States | R01CA262121 | PubMed | NIH RePORTER |
| U01 CA232758 | NCI NIH HHS | United States | U01CA232758 | PubMed and NIH | NIH RePORTER |
| U01 CA176726 | NCI NIH HHS | United States | U01CA176726 | PubMed and NIH | NIH RePORTER |
| T32 CA009140 | NCI NIH HHS | United States | T32CA009140 | PubMed and NIH | NIH RePORTER |
| P01 CA250984 | NCI NIH HHS | United States | P01CA250984 | PubMed | NIH RePORTER |
| R01 CA124515 | NCI NIH HHS | United States | R01CA124515 | PubMed and NIH | NIH RePORTER |
| R01 CA184185 | NCI NIH HHS | United States | R01CA184185 | PubMed and NIH | NIH RePORTER |
| P01CA087969 | NIH | NIH RePORTER | |||
| P30CA076292 | NIH | NIH RePORTER | |||
| R01CA054419 | NIH | NIH RePORTER | |||
| R01CA178687 | NIH | NIH RePORTER | |||
| R01CA211913 | NIH | NIH RePORTER | |||
| R35CA197605 | NIH | NIH RePORTER | |||
| UM1CA176726 | NIH | NIH RePORTER |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 33627799 | IgA strikes twice in ovarian cancer. | https://conductscience.org/library/papers/33627799 | PubMed |
| Comment in | 33974859 | IgA transcytosis: A new weapon in the immune response to cancer? | https://conductscience.org/library/papers/33974859 | PubMed |
Cited by159
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 207 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42856194 | BLTP3A dysfunction unleashes lysosomal stress-induced antitumor immunity through STING. | bioRxiv | 2026 | https://conductscience.org/library/papers/42856194 | PubMed |
| 42846924 | The multifaceted roles of tumor-infiltrating plasma cells in cancer immunology. | Fundam Res | 2026 | https://conductscience.org/library/papers/42846924 | PubMed |
| 42824425 | Why antibody isotype matters for immunotherapy. | Antib Ther | 2026 | https://conductscience.org/library/papers/42824425 | PubMed |
| 42776800 | B Cells and Tumor Immunometabolism: Emerging Insights into Immune Regulation and Therapeutic Resistance. | Antibodies (Basel) | 2026 | https://conductscience.org/library/papers/42776800 | PubMed |
| 42764955 | CMTM6 maintains B cell-intrinsic membrane CD40 stability to regulate anti-tumor immunity. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42764955 | PubMed |
| 42735911 | Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42735911 | PubMed |
| 42706236 | B cells in cancer: functions, mechanisms and therapeutic advances. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42706236 | PubMed |
| 42597660 | B cell receptor-based hybridoma enrichment enables discovery of antibodies against intracellular tumor antigens. | Front Immunol | 2026 | https://conductscience.org/library/papers/42597660 | PubMed |
| 42472098 | Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression. | iScience | 2026 | https://conductscience.org/library/papers/42472098 | PubMed |
| 42456977 | Strategic engineering B cell immunity for cancer immunotherapy. | J Control Release | 2026 | https://conductscience.org/library/papers/42456977 | PubMed |
| 42414574 | Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy. | EMBO Mol Med | 2026 | https://conductscience.org/library/papers/42414574 | PubMed |
| 42380095 | Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42380095 | PubMed |
| 42299115 | Glioma microenvironment: Cellular crosstalk, immunosuppression, and novel therapeutic perspectives. | Chin Med J (Engl) | 2026 | https://conductscience.org/library/papers/42299115 | PubMed |
| 42291273 | Tumor infiltrating B cells and tertiary lymphoid structures in pancreatic cancer prognosis and therapy. | iScience | 2026 | https://conductscience.org/library/papers/42291273 | PubMed |
| 42100745 | Integrated study reveals molecular mechanisms by which bisphenol A promotes ovarian cancer. | iScience | 2026 | https://conductscience.org/library/papers/42100745 | PubMed |
| 42097835 | Endogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42097835 | PubMed |
| 42091692 | Defining the rules of engagement: B cells, antibodies and cancer control. | Cell Mol Immunol | 2026 | https://conductscience.org/library/papers/42091692 | PubMed |
| 41998137 | Neoantigens and shared MICB α3 antigen dual-targeted vaccine generates potent antitumor immunity. | EMBO Mol Med | 2026 | https://conductscience.org/library/papers/41998137 | PubMed |
| 41975230 | Rethinking ovarian cancer III: the past decade and future directions. | Nat Rev Cancer | 2026 | https://conductscience.org/library/papers/41975230 | PubMed |
| 41922487 | Mapping immunosuppressive terrain in high-grade serous ovarian cancer: tumor-intrinsic, stromal, and spatial drivers of therapy response. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/41922487 | PubMed |
Genes32
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33536615
GET https://conductscience.org/api/papers/v1/33536615/authors?page=2